The General Hospital Corporation;Genzyme Corporation
发明人:
申请号：
EP17181294.4
公开号：
EP3254696A1
申请日:
2007.10.03
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-β antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-β antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
